Trimetazidine dihydrochloride.
Each Monitored Release Tablet contains: Trimetazidine (as dihydrochloride) 35 mg.
Trimetazidine is a cardiovascular drug that acts as an effective anti-anginal agent by modulating cardiac energy metabolism. It is an anti-ischaemic metabolic agent that improves myocardial glucose utilization through inhibition of fatty acid metabolism. By preserving the energy metabolism in cells exposed to hypoxia or ischaemia. Trimetazidine prevents a decrease in intracellular adenosine triphosphate levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow while maintaining cellular homeostasis. Trimetazidine also inhibits the oxidation of fatty acid in blood vessels.
Pharmacology: Pharmacokinetics: Trimetazidine after oral administration, absorption of trimetazidine is rapid and the plasma peak is reached in less than 2 hours. After a single oral dose of 35 mg of trimetazidine, the peak plasma concentration is about 55 mg/mL. The apparent volume of distribution is 4.8 L/kg which suggests good tissue diffusion. Elimination of trimetazidine is principally urinary; mean half-life is 6 hours.
Trimetazidine is used for the treatment of angina pectoris and in ischaemia of neurosensorial tissues.
The usual dose is 35 mg two to three times daily with meals or as prescribed by the physician.
Trimetazidine is contraindicated to pregnant and lactating patients and to those who have allergic reactions to the drug.
Trimetazidine is not a curative treatment for angina attacks, nor it is not indicated as an initial treatment for unstable angina, or myocardial infarction. It should be used in the pre-hospital phase nor during the first days of hospitalization. In the event of an angina attack, the coronaropathy should be re-evaluated and an adaptation of the treatment considered drug treatment and possibly revascularization.
Trimetazidine is contraindicated to pregnant and lactating patients.
Trimetazidine causes rare cases of gastrointestinal disorders such as nausea and vomiting.
Since Trimetazidine is non-interaction with MAOIs has not been established. Trimetazidine should not be co-administered with these agents. No other drug interactions have been reported.
Store at temperatures not exceeding 30°C.
C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations.
Ultrazid MR tab 35 mg
30's (P420/box)
Sign Out
